查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1864681

同种异体细胞疗法市场：依最终用户、生产技术、适应症、细胞来源和产品类型划分－2025-2032年全球预测

Allogeneic Cell Therapy Market by End User, Manufacturing Technology, Indication, Cell Source, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，同种异体细胞疗法市场将成长至 67.9 亿美元，复合年增长率为 14.42%。

关键市场统计数据
基准年 2024 23.1亿美元
预计年份：2025年 26.4亿美元
预测年份 2032 67.9亿美元
复合年增长率 (%) 14.42%

从策略角度分析当前异体细胞疗法的发展趋势，重点在于商业化准备、监管协调以及关键的生产挑战。

本执行摘要首先阐明了目前异体细胞疗法的现状，并将这项技术置于再生医学和免疫疗法发展的大背景下进行分析。异体疗法可望实现即时供应、产品品质稳定，并有可能使临床供应摆脱自体移植的限制，从而改变研发者、生产者和支付方的考量。因此，相关人员将投资从个人化生产转向可扩展的生产平台和标准化的管理策略。

同时，临床开发正从概念验证（PoC）阶段迈向更为复杂的试验阶段，以评估药物的持久性、在不同患者群体中的安全性以及真实世界的可行性。监管路径也不断调整，监管机构强调可靠的可比性、效力测定和供应链可追溯性。这要求研发团队在产品设计早期阶段就整合转化科学、程式工程和监管策略。本导言透过重点阐述技术成熟度、商业化准备度和营运要素之间的交集，为后续章节建构框架，这些因素共同决定了专案从临床前景到临床实务的进展。

生物加工技术、免疫工程和商业模式的融合发展如何重塑同种异体细胞疗法的研发路径和投资重点

异体细胞治疗领域正经历着变革性的转变，这主要得益于技术进步、不断变化的监管要求以及商业模式的转型。生产技术的进步，特别是单次使用生物反应器的成熟、微载体系统的改进以及3D培养平台的最佳化，使得细胞产量更高、品质更优，且规模化生产更具可预测性。这些技术变革降低了技术风险，加速了从实验室规模到大量生产的过渡，从而吸引了大量投资进入后期临床专案。

同时，基因编辑和免疫工程技术透过建构通用供体载体、减轻宿主抗移植物反应以及提高体内持久性，正在拓展治疗范围。这些生物学创新正在重塑临床开发策略，并对基因修饰、长期追踪和检测标准化等方面提出了新的监管挑战。随着这些技术的标准化，它们正推动第二波製程创新浪潮，其重点在于将基因工程整合到符合GMP规范的封闭式生产流程中。

商业模式也在改变。支付者和医疗服务提供者越来越重视医疗总成本，并优先考虑能够大规模可靠提供的治疗方法。这种预期促使人们更加关注可重复的生产製造、供应链的韧性以及可证实的长期效益。因此，研发人员、受託研究机构(CRO) 和生产技术供应商之间的伙伴关係变得更加策略性和长期性，强调对共用平台和协作分析开发的投资。这些变化共同加快了整合科学创新、可扩展生产和全面监管策略的计画从药物发现到商业化的进程。

预测新关税对美国细胞治疗生态系统供应链韧性、资本规划和监管合规性的累积影响

美国将于2025年实施的累积关税，可能透过多种机制对整个异体细胞疗法价值链产生连锁反应。首先，对进口试剂、一次性组件和专用设备征收关税，将增加依赖全球供应商的製造商的到岸成本，从而改变研发商和契约製造製造商的成本结构预期。为因应此变化，各机构可能会加快供应本地化、提升国内供应商资质或对关键上游投入进行垂直整合，以降低贸易政策波动带来的风险。

其次，进口成本上升可能导致临床和商业供应的前置作业时间延长，库存策略也更加复杂。拥有多中心临床试验计画的研发企业可能会发现，物流和低温运输需求将更加复杂，促使临床试验中心与製造地部门之间加强合作。这可能会推动供应链区域化，使生产地点更靠近患者群体，减少跨境运输，并降低海关风险。然而，区域生产能力的差异也可能导致不同地区患者取得药物的机会不均等。

第三，关税将影响资本配置决策。随着进口资本设备成本的增加，企业可能会推迟或缩减对先进生物反应器系统和自动化设备的投资计画。相反，他们可能会优先考虑模组化、低产能的解决方案，或利用租赁或供应商融资模式为临床开发提供资金。虽然这种转变会在短期内减缓高通量平台的普及，但也会促进经济高效的生产解决方案的创新。

第四，贸易壁垒可能促使供应商和服务供应商进行策略重组。国际供应商将建立本地生产和分销中心以维持市场进入，而国内製造商可能会扩大产能以满足不断增长的需求。策略联盟、联合生产协议和许可协议可能会增加，以规避关税风险并维持供应的连续性。

最后，关税也将影响监管应对和合规工作。对替代供应商进行资格认证以及调整检验流程以适应不同的零件规格，将增加监管负担和营运复杂性。製造商可能被迫撰写合格研究报告并更新监管申报文件，这可能会延长研发週期，并分散其他优先事项的资源。总而言之，2025年关税的累积效应将促使整个产业重新评估供应链结构、资本计画和监管应对策略。

以细分市场主导的洞察，将最终用户角色、生产平台选择、适应症优先顺序、细胞来源和产品模式与策略发展路径连结起来

分段观点清楚展现了同种异体细胞治疗价值链中各个集中的科学、营运和商业性机会领域。分析最终用户，合约研究组织 (CRO) 是早期和后期研发阶段的重要合作伙伴，提供专业的临床实验物流和流程转移能力；医院和专科诊所则是关键的交付点，需要与临床工作流程和低温运输物流进行整合。研究机构仍然是转化创新和生物标记发现的重要来源，为下游开发平臺提供源源不绝的资源。

製造技术的选择决定了产品特性和成本动态。二维培养系统传统上用于早期研发，在某些工作流程中仍然有用，但必须不断发展以满足堆迭式培养瓶和滚瓶等规模化培养方式的需求。三维球状体培养方法（无论是否使用支架）在仿生微环境能够提高效率的应用中越来越受欢迎。生物反应器系统正日益从多用途转向一次性用途转变，成为实现封闭式製程和降低污染风险的关键。基于微载体的系统，包括固定台和搅拌槽系统，为在保持细胞表型的同时提高细胞密度提供了灵活的方法，但每种技术都需要专门的分析方法和下游製程的调整。

适应症细分突显了治疗重点如何影响产品设计和开发策略。自体免疫疾病，例如红斑性狼疮、多发性硬化症和类风湿性关节炎，需要持续的免疫调节，并具有良好的安全性。心血管适应症，例如心肌梗塞、周边动脉疾病和中风，优先考虑组织修復和功能恢復，这通常需要确保细胞保留和植入的递送策略。传染病应用分为细菌性和病毒性，需要快速部署和可靠的安全性评估。神经系统疾病靶点，例如阿兹海默症、帕金森氏症和脊髓损伤，面临着递送障碍和长期疗效持久性的需求，而感染疾病骨髓恶性肿瘤和固态肿瘤的肿瘤应用则对疗效提出了严格的要求，并需要復杂的联合治疗策略。

细胞来源和产品类型会进一步影响生产和监管策略。每种来源，例如脂肪组织、骨髓、週边血和脐​​带血，在采集物流、细胞产量和供体差异方面都具有独特的特征，从而影响上游工程处理和供体筛检。产品类型，例如 CAR-T 构建体、树突细胞疗法、NK 细胞疗法和各种干细胞疗法，都需要专门的基因工程、活化和扩增流程。基因编辑与非基因编辑的 CAR-T、未分化与成熟的树突状细胞製剂、修饰与未修饰的 NK 细胞以及造血干细胞疗法与间质干细胞疗法等子类别提出了额外的分析和可比性要求。事实上，最有前景的项目将根据适应症的生物学特性，选择优化的细胞来源和生产平台，以满足临床需求，同时最大限度地降低製程复杂性。

影响临床策略、製造地和市场进入的区域趋势和战略要务（美洲、欧洲/中东/非洲、亚太地区）

区域趋势对在美洲、欧洲、中东和非洲以及亚太地区营运的相关人员提出了不同的需求。美洲地区临床活动高度集中，且在製造基础设施方面投入巨大，这既有利于快速实用化，也加剧了对熟练人才和专业设施的竞争。因此，在该地区营运的公司越来越重视扩充性的模组化製造系统和策略合作伙伴关係，以加快临床试验进程。

在欧洲、中东和非洲地区，各司法管辖区的法规结构和市场进入政策各不相同，这会影响跨国临床策略以及商业化进程的先后顺序。儘管协调努力和合作网络有助于跨国临床计画的进行，但研发人员仍需应对不同的报销模式和各国监管细则。该地区通常鼓励建立强大的「卓越中心」模式，将复杂的治疗流程集中在专业机构进行。

亚太地区正经历快速的临床扩张、不断提升的生产能力以及对公私合营的强烈需求。当地对细胞疗法研究的投资以及日益壮大的本土供应商生态系统，为优化成本结构和实现本地化生产创造了机会。然而，研发人员必须考虑监管成熟度的差异以及临床试验设计和上市后监测标准的差异。在所有地区，跨境合作和製造地的选择都将决定专案的韧性、病患可近性和长期永续性。

企业策略、伙伴关係和生产能力决定了细胞疗法开发中的竞争定位和业务永续营运

每家公司的策略都代表着其在异体细胞治疗生态系统中应对竞争与合作的独特方式。领先的研发公司正集中资源将差异化科学转化为临床优势，同时建构或巩固后期临床试验和商业化所需的生产能力。契约製造组织 (CMO) 和专业技术供应商发挥关键作用，它们提供可扩展的平台和监管方面的专业知识，使规模较小的研发公司无需大量资本投入即可运作。

策略联盟、授权协议和选择性垂直整合是应对大规模生产产品品质一致性挑战的常见方法。早期投资稳健的分析开发和功效测试的公司可以降低下游产品可比性风险，并加速与监管机构的沟通。此外，供应商多元化并对关键原材料的替代来源进行资格认证的公司，在应对供应中断方面表现出更强的韧性。

竞争优势将取决于企业如何管理其智慧财产权、基因编辑平台和细胞工程技术。那些建立完善的生产知识转移流程并投资于员工发展的企业，将实现更可靠的技术转移和更快的规模化生产。最后，企业策略将日益体现商业性考量，例如与支付方的合作、真实世界疗效的证据生成，以及将治疗药物供应与培训和现场支援相结合的服务型产品。

为经营团队提供切实可行的建议，以协调转化科学、生产规模化、供应链韧性和支付方合作，从而推动商业成功。

产业领导者应采取一系列切实可行的措施，使科学目标与营运可行性和商业性永续性一致。首先，应优先考虑整合製程开发，在专案设计初期就同时优化细胞产品特性和可扩展的生产工艺，以避免后期开发中高成本的重新设计。儘早协调转化科学、程式工程和监管策略，将缩短临床试验时间，并增强监理申报的效力。

第二，应实现关键耗材和零件来源多元化，并尽可能合格国内标准的替代品，以降低关税和地缘政治风险。确保供应链多元化，并制定与临床里程碑相关的库存策略，将有助于保障临床实验的连续性和商业化准备。第三，必须投资建立强大的分析平台，并进行疗效研究，以阐明作用机制和临床相关性。强有力的分析证据，将生产控制与临床结果连结起来，将有助于与监管机构和支付者沟通。

第四，考虑采用灵活的生产模式，将内部生产能力与策略性契约製造组织 (CMO) 结合。这种混合模式既能有效控制关键流程，也能根据临床和商业需求快速扩大生产规模。第五，儘早与支付方和医疗系统接洽，明确价值评估架构、真实世界证据要求和交付路径。积极参与有助于降低报销的不确定性，并有助于确定对相关人员至关重要的临床试验终点。

最后，要透过以细胞疗法生产、品质系统和法规遵循为重点的招募和培训计画来培养人才。人才仍然是瓶颈，投资于能力建设将加速商业化进程并提高营运品质。所有这些努力将共同建构一条从实验室创新到永续患者获取的稳健且扩充性的路径。

为了支持实际研究结果，我们采用了混合方法研究检验，结合了文献综合、专家访谈、技术检验和案例研究三角验证。

本分析采用混合方法，整合定性和定量数据，旨在确保分析的严谨性和相关性。为了解技术、临床开发和政策方面的潜在趋势，我们收集了最新的科学文献、同行评审的转化研究、监管指导文件、临床试验註册资讯以及上市公司披露资讯。这些资讯来源提供了必要的技术和监管背景，有助于解读基因编辑、细胞工程和生产方法领域的最新进展。

除了文献研究外，我们还对包括开发人员、契约製造、临床研究人员和法规事务专业人员在内的相关领域专家进行了结构化访谈，以了解实际营运和策略意图。我们将访谈结果与设备和试剂供应商提供的製程描述和技术规格进行三角验证，检验关于扩充性、可比较性和供应链依赖性的检验。在适用情况下，我们还利用了近期製程转移和规模化生产的匿名案例研究，以得出关于风险缓解措施和资源分配的实用指导。

本研究透过交叉检验结论、评估方法偏差以及明确承认数据局限性，确保了分析的严谨性。研究强调可重复的方法和透明的假设，并指出了哪些领域需要进一步收集一手资料以辅助决策。调查方法力求在深入洞察的同时，为企业主管和技术领导者提供切实可行的建议。

对技术准备、业务永续营运和监管合规性如何决定哪些同种异体移植项目能够取得持续的临床和商业性影响的评估

总之，异体细胞治疗领域正处于一个转折点，技术成熟度、供应链策略和监管合规性将共同决定哪些计画能够获得持续的临床和商业性成功。现成产品有潜力扩大患者群体并简化给药模式，但要实现这一潜力，需要在科学设计、生产扩充性和支付方合作方面进行有意识的协调。

营运韧性，包括多元化的采购管道、强大的分析能力和灵活的生产製造，将决定行业领导者与落后者之间的差距。同时，围绕基因编辑技术、疗效测试和上市后监测的监管政策的清晰度将影响研发重点和证据生成策略。最后，区域扩张决策和对贸易政策变化的应对措施将对成本结构和市场准入途径产生重大影响。能够将这些要素整合到统一研发计画中的机构，将更有能力将临床潜力转化为对病患的持续影响。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过扩大模组化自动化製造平台规模来降低同种异体移植生产成本和週期时间
  • 建立源自经HLA编辑的通用供体iPS细胞的细胞库，以最大程度地降低移植排斥风险
  • 监管协调工作旨在指导各地区同种异体细胞疗法的临床试验设计
  • 推出冷冻保存创新技术，可延长预製细胞产品的保质期并实现全球分销
  • 整合基因编辑工具以提高同种异体细胞移植的免疫逃脱能力和持久性
  • 生技公司与合约研发生产力机构（CDMO）建立策略联盟，加速扩大商业化同种异体疗法生产基地
  • 现成的同种异体NK细胞疗法在骨髓恶性肿瘤恶性肿瘤和固态肿瘤治疗的应用
  • 下一代同种异体细胞疗法的投资趋势主要集中在自体免疫和退化性疾病的适应症。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 以最终用户分類的同种异体细胞疗法市场

  • CRO（合约研究组织）
  • 医院
  • 研究所
  • 专科诊所

9. 依製造技术分類的同种异体细胞疗法市场

  • 二维培养系统
    • 堆迭烧瓶
    • 滚珠瓶
  • 3D球状体培养
    • 鹰架底座
    • 无支架
  • 生物反应器系统
    • 多用途
    • 一次使用
  • 基于微载体的系统
    • 固定台
    • 搅拌槽

第十章 依适应症分類的同种异体细胞疗法市场

  • 自体免疫疾病
    • 狼疮
    • 多发性硬化症
    • 类风湿性关节炎
  • 心血管疾病
    • 心肌梗塞
    • 周边动脉疾病
    • 中风
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 神经系统疾病
    • 阿兹海默症
    • 帕金森氏症
    • 脊髓损伤
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤

第十一章 依细胞来源分類的同种异体细胞疗法市场

  • 脂肪组织
  • 骨髓
  • 週边血
  • 脐带

第十二章 依产品类型分類的同种异体细胞疗法市场

  • CAR-T疗法
    • 基因编辑
    • 非基因编辑
  • 树突细胞疗法
    • 未分化树突状细胞
    • 成熟树突状细胞
  • NK细胞疗法
    • 修改
    • 未修改
  • 干细胞疗法
    • 造血干细胞
    • 间质

第十三章 各地区同种异体细胞疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 同种异体细胞疗法市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国同种异体细胞疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Allogene Therapeutics, Inc.
    • Mesoblast Limited
    • Atara Biotherapeutics, Inc.
    • Gamida Cell Ltd.
    • Celularity, Inc.
    • Celyad Oncology SA
    • Cellectis SA
    • Cellular Biomedicine Group, Inc.
Product Code: MRR-CA100284D019

The Allogeneic Cell Therapy Market is projected to grow by USD 6.79 billion at a CAGR of 14.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.31 billion
Estimated Year [2025] USD 2.64 billion
Forecast Year [2032] USD 6.79 billion
CAGR (%) 14.42%

A strategic orientation to the current allogeneic cell therapy landscape that highlights commercialization readiness, regulatory alignment, and manufacturing imperatives

This executive summary opens with a clear orientation to the current allogeneic cell therapy landscape, situating the technology within the broader evolution of regenerative medicine and immunotherapy. Allogeneic approaches promise off-the-shelf availability, consistent product quality, and the potential to decouple clinical supply from autologous constraints, which changes the calculus for developers, manufacturers, and payers. As a result, stakeholders are shifting investments from one-off individualized production toward scalable manufacturing platforms and standardized control strategies.

In parallel, clinical development is moving beyond proof-of-concept into more complex trials that evaluate durability, safety across diverse patient populations, and real-world deliverability. Regulatory pathways are adapting, with agencies emphasizing robust comparability, potency assays, and supply chain traceability. Consequently, development teams must integrate translational science, process engineering, and regulatory strategy earlier in product design. This introduction frames the subsequent sections by highlighting the intersection of technology maturation, commercialization readiness, and the operational imperatives that determine which programs will progress from clinical promise to clinical practice.

How convergent advances in bioprocess technologies, immune engineering, and commercial models are reshaping development pathways and investment priorities in allogeneic cell therapy

The allogeneic cell therapy arena is experiencing transformative shifts driven by converging technological advances, evolving regulatory expectations, and shifting commercial models. Advances in manufacturing technology, including the maturation of single-use bioreactors, refined microcarrier systems, and three-dimensional culture platforms, are enabling higher yields, improved cell quality, and more predictable scalability. These technological changes reduce technical risk and accelerate the transition from bench to batch, which in turn attracts broader investment into late-stage clinical programs.

Concurrently, gene editing and immune engineering techniques are expanding the therapeutic scope by enabling universal donor constructs, alleviating host-versus-graft reactions, and improving persistence in vivo. These biological innovations are reshaping clinical development strategies and creating new regulatory questions around genetic modification, long-term follow-up, and assay standardization. As these techniques become more standardized, they drive a secondary wave of process innovation focused on integrating genetic manipulation into closed, GMP-compliant production flows.

Commercial models are also shifting. Payers and providers increasingly evaluate total cost of care and prefer therapies that can be delivered reliably at scale. This expectation places a premium on reproducible manufacturing, supply chain resilience, and demonstrable long-term benefits. As a result, partnerships between developers, contract research organizations, and manufacturing technology suppliers are becoming more strategic and long-term in nature, emphasizing shared platform investments and co-development of analytic methods. Taken together, these shifts compress timelines from discovery to commercialization for programs that align scientific innovation with scalable manufacturing and comprehensive regulatory strategies.

Projected cumulative impacts of new tariff measures on supply chain resilience, capital planning, and regulatory compliance within the United States cell therapy ecosystem

The introduction of cumulative United States tariffs in 2025 has the potential to reverberate across the allogeneic cell therapy value chain through several distinct mechanisms. First, tariffs on imported reagents, single-use components, and specialized equipment will increase landed costs for manufacturers that rely on global suppliers, thereby altering cost-structure assumptions for both developers and contract manufacturers. In response, organizations may accelerate efforts to localize supply, qualify domestic suppliers, or vertically integrate critical upstream inputs to reduce exposure to trade policy volatility.

Second, increased import costs can lengthen lead times and complicate inventory strategies for clinical and commercial supply. Developers running multi-site clinical programs may find logistics and cold-chain requirements more complex, prompting tighter coordination between clinical sites and manufacturing centers. This could encourage regionalization of supply chains, where production closer to patient populations reduces cross-border movement and mitigates tariff exposure, but it may also create disparities in access if regional manufacturing capacity is uneven.

Third, tariffs can influence capital allocation decisions. When imported capital equipment becomes more expensive, companies may delay or downsize planned investments in advanced bioreactor systems or automation. Conversely, they may prioritize modular, lower-capex solutions or seek leasing and vendor finance models to preserve capital for clinical development. This shift can slow the adoption of higher-throughput platforms in the short term while stimulating innovation in cost-effective manufacturing solutions.

Fourth, trade barriers tend to catalyze strategic realignments among suppliers and service providers. International suppliers may establish local production or distribution arms to retain market access, while domestic manufacturers could expand capacity to meet rising demand. Strategic partnerships, co-manufacturing agreements, and licensing arrangements may proliferate as firms seek to hedge tariff risk and maintain supply continuity.

Lastly, tariffs have implications for regulatory and compliance efforts. The need to qualify alternative suppliers and adapt validated processes to different component specifications increases the regulatory burden and operational complexity. Manufacturers will need to document comparability studies and potentially update regulatory filings, which can extend timelines and divert resources from other development priorities. Overall, the cumulative effect of tariffs in 2025 encourages a reappraisal of supply chain architecture, capital planning, and regulatory contingency strategies across the sector.

Segment-driven insights that map end-user roles, manufacturing platform choices, indication priorities, cell sources, and product modalities to strategic development pathways

A segmentation-driven view clarifies where scientific, operational, and commercial opportunities cluster across the allogeneic cell therapy value chain. When examining end users, Contract Research Organizations act as essential partners for early and late-stage development, providing specialized trial logistics and process transfer capabilities, whereas hospitals and specialty clinics function as primary delivery points that require integration with clinical workflows and cold-chain logistics. Research institutes remain critical sources of translational innovation and biomarker discovery that feed downstream development pipelines.

Manufacturing technology choices shape both product attributes and cost dynamics. Two-dimensional culture systems, historically used for early development, remain relevant for specific workflows but must evolve to meet scale demands through layered flasks and roller bottle formats. Three-dimensional spheroid culture approaches, whether scaffold-based or scaffold-free, are gaining traction for applications where native-like microenvironments enhance potency. Bioreactor systems, transitioning between multi-use and single-use configurations, are central to achieving closed-system processing and reducing contamination risk. Microcarrier based systems, including fixed bed and stirred tank variants, provide flexible routes to increase cell density while preserving phenotype, yet each technology requires bespoke analytics and downstream processing adaptations.

Indication segmentation highlights how therapeutic focus influences product design and development strategy. Autoimmune disorders such as lupus, multiple sclerosis, and rheumatoid arthritis demand durable immunomodulation with favorable safety margins. Cardiovascular indications like myocardial infarction, peripheral artery disease, and stroke prioritize tissue repair and functional recovery, which often requires delivery strategies that ensure cell retention and engraftment. Infectious disease applications, divided between bacterial and viral infections, necessitate rapid deployability and robust safety profiling. Neurological targets including Alzheimer's, Parkinson's, and spinal cord injury confront delivery barriers and the need for long-term durability, while oncology applications for hematological malignancies and solid tumors impose stringent efficacy thresholds and complex combination strategies.

Cell source and product type further influence manufacturing and regulatory strategy. Sources such as adipose tissue, bone marrow, peripheral blood, and umbilical cord each present unique harvest logistics, cell yields, and donor variability that affect upstream processing and donor screening. Product types including CAR-T constructs, dendritic cell therapies, NK cell therapies, and diverse stem cell approaches demand tailored genetic engineering, activation, and expansion workflows. Subcategories-such as gene edited versus non-gene edited CAR-T, immature versus mature dendritic cell preparations, engineered versus unmodified NK cells, and hematopoietic versus mesenchymal stem cell therapies-introduce additional analytical and comparability requirements. In practice, the most promising programs align indication biology with an optimized cell source and manufacturing platform that together address clinical need while minimizing process complexity.

Regional dynamics and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape clinical strategy, manufacturing footprint, and market access

Regional dynamics create differentiated imperatives for stakeholders operating across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit concentrated clinical activity and substantial investment into manufacturing infrastructure, which supports rapid translation but also heightens competition for skilled talent and specialized facility capacity. Consequently, firms operating here often emphasize scalable, modular manufacturing systems and strategic partnerships to accelerate time to clinic.

Within Europe, Middle East & Africa, regulatory frameworks and market access policies vary across jurisdictions, shaping multi-country clinical strategies and commercial launch sequencing. Harmonization efforts and collaborative networks foster cross-border clinical programs, but developers must navigate diverse reimbursement models and national regulatory nuances. This region typically encourages strong center-of-excellence models that concentrate complex procedures at specialized institutions.

The Asia-Pacific region combines rapid clinical expansion with growing manufacturing capabilities and an appetite for public-private collaboration. Local investment in cell therapy research and domestic supplier ecosystems is increasing, creating opportunities to optimize cost structures and localize production. However, developers must account for heterogeneous regulatory maturity and varying standards for clinical trial design and post-market surveillance. Across all regions, cross-border collaboration and manufacturing footprint decisions will determine program resilience, patient access, and long-term sustainability.

How corporate strategies, partnerships, and manufacturing capabilities define competitive positioning and operational resilience in cell therapy development

Company strategies reveal distinct approaches to competing and collaborating within the allogeneic cell therapy ecosystem. Leading developers concentrate resources on translating differentiating science into clinical advantage while building or securing access to the manufacturing capacity required for late-stage trials and commercialization. Contract manufacturing organizations and specialized technology suppliers play a pivotal role by offering scalable platforms and regulatory expertise that enable smaller developers to advance without large capital expenditures.

Strategic partnerships, licensing agreements, and selective vertical integration are common responses to the challenge of delivering consistent product quality at scale. Firms that invest early in robust analytical development and potency assays reduce downstream comparability risk and accelerate regulatory interactions. Moreover, companies that diversify supplier bases and qualify alternative sources for critical raw materials demonstrate greater resilience to supply disruptions.

Competitive positioning also depends on how firms manage intellectual property, gene-editing platforms, and cell engineering know-how. Organizations that cultivate strong manufacturing knowledge transfer processes and invest in workforce training produce more reliable technology transfers and faster scale-up. Finally, corporate strategies increasingly reflect commercial considerations such as payer engagement, evidence generation for real-world outcomes, and the development of service-oriented offerings that bundle therapy supply with training and site support to facilitate adoption.

Practical recommendations for executives to align translational science, manufacturing scale-up, supply chain resilience, and payer engagement to drive commercialization success

Industry leaders should pursue a set of actionable measures that align scientific ambition with operational feasibility and commercial viability. First, prioritize integrated process development that co-optimizes cell product attributes and scalable manufacturing early in program design to avoid costly redesigns later in development. Early alignment between translational science, process engineering, and regulatory strategy reduces time to clinic and strengthens regulatory submissions.

Second, diversify supplier relationships for critical consumables and components while qualifying domestic alternatives where feasible to mitigate tariff and geopolitical risks. Securing multi-sourced supply chains and building inventory strategies tied to clinical milestones will protect trial continuity and commercial launch readiness. Third, invest in robust analytical platforms and potency assays that demonstrate mechanism of action and clinical relevance. Strong analytical evidence supports both regulatory interactions and payer discussions by connecting manufacturing control to clinical outcomes.

Fourth, consider flexible manufacturing models that combine internal capacity with strategic use of contract manufacturing organizations. This hybrid approach balances control over critical processes with the ability to scale rapidly when clinical or commercial demand materializes. Fifth, engage payers and health systems early to define value frameworks, real-world evidence requirements, and delivery pathways. Proactive engagement reduces reimbursement uncertainty and informs clinical trial endpoints that matter to stakeholders.

Finally, cultivate talent through targeted hiring and training programs focused on cell therapy manufacturing, quality systems, and regulatory affairs. Workforce readiness remains a bottleneck; investing in capability development will accelerate commercialization and improve operational quality. Together, these actions create a resilient, scalable pathway from laboratory innovation to sustainable patient access.

A mixed-method research approach combining literature synthesis, expert interviews, technology validation, and case study triangulation to underpin actionable insights

This analysis synthesizes qualitative and quantitative inputs using a mixed-method approach designed to ensure rigor and relevance. We compiled contemporary scientific literature, peer-reviewed translational studies, regulatory guidance documents, clinical trial registries, and publicly available corporate disclosures to establish baseline trends in technology, clinical development, and policy. These sources provided the technical and regulatory context necessary to interpret recent advances in gene editing, cell engineering, and manufacturing modalities.

We complemented documentary research with structured interviews of domain experts spanning developers, contract manufacturers, clinical investigators, and regulatory affairs professionals to capture operational realities and strategic intent. Interview findings were triangulated with process descriptions and technology specifications from equipment and reagent suppliers to validate assumptions about scalability, comparability, and supply chain dependencies. Where applicable, anonymized case studies of recent process transfers and scale-up efforts informed practical guidance on risk mitigation and resource allocation.

Analytic rigor was maintained through cross-validation of claims, assessment of methodological biases, and explicit acknowledgement of data limitations. The study emphasizes reproducible methods and transparent assumptions, and it identifies areas where further primary data collection would strengthen decision-making. This methodology balances depth of insight with the need for actionable recommendations targeted to executives and technical leaders.

Concluding synthesis on how technological readiness, operational resilience, and regulatory alignment will determine which allogeneic programs achieve sustained clinical and commercial impact

In conclusion, the allogeneic cell therapy field stands at an inflection point where technological maturation, supply chain strategy, and regulatory adaptation converge to determine which programs will achieve durable clinical and commercial success. Off-the-shelf products can unlock broader patient access and streamlined delivery models, but realizing that potential requires deliberate alignment across scientific design, manufacturing scalability, and payer engagement.

Operational resilience-evidenced by diversified sourcing, robust analytics, and flexible manufacturing-will distinguish leaders from laggards. Meanwhile, regulatory clarity around gene editing, potency assays, and post-market surveillance will shape development priorities and evidence generation strategies. Finally, regional footprint decisions and responses to trade policy shifts will materially affect cost structures and access pathways. The organizations that integrate these dimensions into coherent development programs will be best positioned to translate clinical promise into sustained patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Scale-up of modular automated manufacturing platforms to reduce allogeneic production costs and cycle times
  • 5.2. Development of universal donor iPSC-derived cell banks with HLA editing to minimize graft rejection risk
  • 5.3. Regulatory harmonization efforts guiding clinical trial design for allogeneic cell therapies across regions
  • 5.4. Adoption of cryopreservation innovations enabling extended shelf life and global distribution of off-the-shelf cell products
  • 5.5. Integration of gene-editing tools to enhance immune evasion and persistence of allogeneic cell grafts
  • 5.6. Strategic partnerships between biotech companies and CDMOs to accelerate commercial allogeneic therapy manufacturing footprints
  • 5.7. Emergence of off-the-shelf allogeneic NK cell therapies targeting hematologic and solid malignancies
  • 5.8. Investment trends in next-generation allogeneic cell therapies focusing on autoimmune and degenerative disease indications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allogeneic Cell Therapy Market, by End User

  • 8.1. Contract Research Organization
  • 8.2. Hospital
  • 8.3. Research Institute
  • 8.4. Specialty Clinic

9. Allogeneic Cell Therapy Market, by Manufacturing Technology

  • 9.1. 2D Culture Systems
    • 9.1.1. Layered Flasks
    • 9.1.2. Roller Bottles
  • 9.2. 3D Spheroid Culture
    • 9.2.1. Scaffold Based
    • 9.2.2. Scaffold Free
  • 9.3. Bioreactor Systems
    • 9.3.1. Multi Use
    • 9.3.2. Single Use
  • 9.4. Microcarrier Based Systems
    • 9.4.1. Fixed Bed
    • 9.4.2. Stirred Tank

10. Allogeneic Cell Therapy Market, by Indication

  • 10.1. Autoimmune Disorders
    • 10.1.1. Lupus
    • 10.1.2. Multiple Sclerosis
    • 10.1.3. Rheumatoid Arthritis
  • 10.2. Cardiovascular Diseases
    • 10.2.1. Myocardial Infarction
    • 10.2.2. Peripheral Artery Disease
    • 10.2.3. Stroke
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial Infections
    • 10.3.2. Viral Infections
  • 10.4. Neurological Disorders
    • 10.4.1. Alzheimers
    • 10.4.2. Parkinsons
    • 10.4.3. Spinal Cord Injury
  • 10.5. Oncology
    • 10.5.1. Hematological Malignancies
    • 10.5.2. Solid Tumors

11. Allogeneic Cell Therapy Market, by Cell Source

  • 11.1. Adipose Tissue
  • 11.2. Bone Marrow
  • 11.3. Peripheral Blood
  • 11.4. Umbilical Cord

12. Allogeneic Cell Therapy Market, by Product Type

  • 12.1. CAR-T Therapy
    • 12.1.1. Gene Edited
    • 12.1.2. Non Gene Edited
  • 12.2. Dendritic Cell Therapy
    • 12.2.1. Immature Dendritic
    • 12.2.2. Mature Dendritic
  • 12.3. NK Cell Therapy
    • 12.3.1. Engineered
    • 12.3.2. Unmodified
  • 12.4. Stem Cell Therapy
    • 12.4.1. Hematopoietic
    • 12.4.2. Mesenchymal

13. Allogeneic Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Allogeneic Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Allogeneic Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Allogene Therapeutics, Inc.
    • 16.3.2. Mesoblast Limited
    • 16.3.3. Atara Biotherapeutics, Inc.
    • 16.3.4. Gamida Cell Ltd.
    • 16.3.5. Celularity, Inc.
    • 16.3.6. Celyad Oncology SA
    • 16.3.7. Cellectis SA
    • 16.3.8. Cellular Biomedicine Group, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LAYERED FLASKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ROLLER BOTTLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY 3D SPHEROID CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SCAFFOLD FREE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOREACTOR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTI USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MICROCARRIER BASED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY FIXED BED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STIRRED TANK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY GENE EDITED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NON GENE EDITED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY IMMATURE DENDRITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MATURE DENDRITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2024 (USD MILLIO